



PCT/EP200 4 / 0 0 8 7 0 3

02. 08. 2004



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 23 SEP 2004

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

**PRIORITY
DOCUMENT**


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed

Dated


26 July 2004

Stephen Horrell



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

RFW/ND/VB60431P

2. Patent application number

(The Patent Office will fill in his part)

0318242.5

- 4 AUG 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames)

GlaxoSmithKline Biologicals s.a.
Rue de l'Institut 89, B-1330 Rixensart, , Belgium

Patents ADP number (if you know it)

Belgian

If the applicant is a corporate body, give the country/state of its incorporation

8101271201

4. Title of the invention

Novel Device

5. Name of your agent (if you have one)

Corporate Intellectual Property

"Address for service" in the United Kingdom to which all correspondence should be sent

(including the postcode)

GlaxoSmithKline
Corporate Intellectual Property (CN9 25.1)
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

Patents ADP number (if you know it)

8072555204

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	---	--

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	--

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer yes if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is named as an applicant, or
 - c) any named applicant is a corporate body
- See note (d)

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description ← 11

Claim(s) ← 4

Abstract

Drawings ← 1



10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

We request the grant of a patent on the basis of this application

Signature

R F Walker

Date 4-Aug-03

12. Name and daytime telephone number of person to contact in the United Kingdom

R F Walker 020 80474485

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- For details of the fee and ways to pay please contact the Patent Office.*

Patents Form 1/77

Novel Device

This invention relates to a novel product comprising a novel elastomer material, to uses of this elastomer material, to products made using it, and processes for making and using it.

5 Elastomer materials are well known and have innumerable uses. A particular use is for the manufacture of closures for pharmaceutical vials and plungers for hypodermic syringes.

 Drug substance and vaccine products are frequently provided in vials which are closed with an elastomer closure part through which a hollow needle can be
10 passed, puncturing the closure part, and via which the drug substance or vaccine product may be extracted for use, optionally after reconstitution by an aqueous medium introduced into the vial via the needle. Normally such a vial has a mouth opening bounded by a flange-shaped rim, and the closure part is held in a closing relationship with the mouth opening by a flexible metal clamp part which surrounds
15 the perimeter of the closure part and holds it tightly against the rim.

 It is also known, e.g. from WO-A-02/064439, to provide a pharmaceutical vial having a closure part made partly of thermoplastic elastomer material, and e.g. from WO-A-03/028785 to provide a hypodermic syringe having a plunger made partly of a thermoplastic elastomer material. Such a vial or syringe can be filled
20 using a hollow needle passed through the closure part or plunger respectively, the needle is then withdrawn, and the small residual puncture hole in the closure or plunger may then be sealed by heat sealing, e.g. using a focussed laser beam.

 Known elastomer materials present problems when they are used as a material for the closure part or plunger disclosed respectively in WO-A-02/064439
25 and WO-A-03/028785. For example known polymers generate smoke as they are heated by the laser beam, which may contaminate the contents of the vial. Known polymers also have a low diffusion of the laser power so that a significant proportion of the laser power can pass through the closure or plunger to the contents of the vial or syringe, possibly damaging the contents.

30 It is an object of this invention to address these problems of the state of the art. Other objects and advantages of the invention will be apparent from the following description.

According to this invention an elastomer material is provided, having an absorption coefficient for laser light of $0.5 - 2.5 \text{ mm}^{-1}$.

As will be seen below the principal intended use of the elastomer material of the invention is for pharmaceutical vial closures and plungers for hypodermic syringes in which a residual puncture hole can be made and sealed by melting the elastomer material adjacent the residual puncture hole with a beam of laser radiation directed at the site of the puncture. For this purpose suitably the base TPE has a melting point less than 200°C , preferably 180°C or less. The base thermoplastic elastomer ("TPE") may also be selected on the basis of properties known to be suitable for use as vial closures and plungers, e.g. elasticity, hardness, compatibility with pharmaceutical uses etc.

Preferably the elastomer material of the invention comprises a base thermoplastic elastomer compounded with a colourant to have the absorption coefficient for laser light of $0.5 - 2.5 \text{ mm}^{-1}$.

Preferably the base TPE is a styrene-ethylene/butylene-styrene ("SEBS") thermoplastic elastomer. Such elastomers are well known, e.g. based on known Kraton™ SEBS elastomers, with a resin modifier which interacts with the polystyrene end blocks, essentially increasing their size and their effective glass transition temperature. Such elastomers have low compression set at room temperature, i.e. when stretched they show little tendency to neck, making them suitable for sealing against rigid surfaces, such as the mouths and necks of pharmaceutical vials. A preferred type of SEBS elastomer is that available under the name Evoprene™ for example from Alphagary, particularly materials available under the name Evoprene™ Super G, in particular Evoprene™ Super G 948, Evoprene™ TS2525 also being suitable but having a less favourable water permeability than Super G 948. Other suitable SEBS elastomers include that available under the name Cawiton™, e.g. Cawiton™ PR5947 available from Wittenburg (NL) and C-Flex R70-001 available from CPT (USA). SEBS elastomer materials with similar properties to these would also be suitable.

Other types of base TPE may be used, for example styrene/butadiene/styrene ("SBS") tri-block copolymers, and styrene-(butadiene/butylene)-styrene ("SBBS") tri-block copolymers.

The colourant imparts a colour to the elastomer material of the invention. The property of having a colour inherently means that light of certain wavelength is absorbed rather than transmitted by the coloured material, and it is principally the colour of the elastomer that is responsible for the absorption coefficient. The colour
5 imparted is not critical provided that the defined absorption coefficient is achieved. It is believed that depth of colour rather than the colour itself is the important factor in determining the absorption coefficient, but a grey colour is suitable.

The colourant preferably comprises a pigment or a mixture thereof mixed with a carrier material. The carrier material is suitably a polymer which can be
10 compounded with the elastomer. Such colourants are commonly used in the field of manufacture of polymer, including elastomer, products and the mixture of pigment and carrier material is known as a "masterbatch". It is a standard process in this field to prepare a colour masterbatch of a defined colour and/or composition which can easily be reproduced, and to compound this masterbatch in a defined ratio with
15 a bulk of elastomer to produce an elastomer of a reproducible colour.

A suitable pigment has the grey-green colour Pantone 5497C or a similar grey colour. The Pantone Matching System (PMS) is a system shared world wide by the graphic arts industry. Similar colours include Pantone 556C, 5565C, 563C, 570C, 5555C. Suitably a mixture of pigments may comprise a mixture of the
20 pigments: white 6, black 7, green 7 and blue 29. These pigments are also standard nomenclature in the art, e.g. as referenced under their INCI name. It will be apparent to those skilled in the art how to prepare a pigment of colour Pantone 5497C or a similar grey colour using such pigments.

Various suitable carrier materials for TPE's are known in the art. For
25 example ethylene vinyl acetate (EVA), low density polyethylene (LDPE) and polypropylene (PP).

The amount of pigment used in the colourant to make the masterbatch, and the amount of the colourant masterbatch mixed with the elastomer will vary from application to application, for example depending upon the natural colour of the
30 SEBS thermoplastic elastomer, but can be determined empirically to achieved the desired absorption coefficient. For example the colourant mixture may comprise 10 - 50 wt. % pigment, the balance up to 100% comprising the carrier material.

Typically the elastomer material of the invention may comprise 1 – 15wt.%, preferably 1 – 10wt.% of colourant (masterbatch), the balance up to 100% comprising the base TPE. Compounding of the masterbatch with the base TPE is a well known conventional procedure.

- 5 A preferred elastomer material of the invention comprises Evoprene™ Super G, compounded with 1 – 5 wt%, especially 1.2 – 2 wt% of a colourant masterbatch comprising an EVA carrier with 35 - 45wt% of pigment of a colour Pantone 5497 or similar colour, e.g. based on the mixture of pigments listed above.

- 10 Another suitable elastomer material of the invention comprises Evoprene™ TS2525, compounded with 1 – 5 wt%, especially 1.2 – 2 wt% of a colourant masterbatch comprising an EVA carrier with 35 - 45wt% of pigment of a colour Pantone 5497 or similar colour, e.g. based on the mixture of pigments listed above.

- 15 Another suitable elastomer material of the invention comprises Cawiton™ PR5947, compounded with 3 - 15 wt% of a colourant masterbatch comprising an LDPE carrier with 15 – 20 wt% of pigment of a colour Pantone 5497 or similar colour, e.g. based on the mixture of pigments listed above.

- 20 The absorption coefficient may relate to the thickness in mm of the elastomer material in which 99% of laser radiation energy incident upon a surface of the elastomer material is absorbed. If the laser radiation is absorbed too close to the surface upon which the radiation impinges then the surface can become too hot when used in the principal intended use outlined above and smoke and other pyrolytic decomposition products may be emitted. If the laser radiation is not absorbed by the thickness of a pharmaceutical vial closure or plunger it may pass through and affect the contents of the vial or syringe. Typically the thickness of the part of a vial closure to be used in the above mentioned purpose is ca. 2mm and it is preferred that at an incident laser power of up to 8W less than 6% of the laser power passes through. Although the laser radiation wavelength is not critical a wavelength of 980nm is suitable, at a laser power of up to ca. 20W, preferably up to ca. 4 – 10W, e.g. ca. 8.0 +/- 0.5W. The absorption coefficient is preferably in the range 1.0 – 2.5 mm⁻¹ preferably 1.5 – 2.2 mm⁻¹, ideally as close to 1.5 mm⁻¹ as can be achieved, e.g. 1.4 – 1.6 mm⁻¹.
- 25
- 30

The absorption coefficient α may be measured using methods apparent to those skilled in the art based on the Beer-Lambert law. One such method involves relating incident laser power arriving at the incident surface (P_i) to the laser power transmitted through the material (P_t) i.e. emerging from the opposite surface, in the relationship:

$$P_t = P_i \times \exp^{-\alpha L}$$

Where α is the absorption coefficient and L is the thickness of the material. For example a measuring system may comprise a suitable laser of power low enough that the properties of the material are not affected e.g. by thermal decomposition e.g. generating 200 – 400 mW directing the laser light along a suitable light guide, e.g. an optic fibre, toward a power measuring instrument. The laser power detected in the absence of any material between the light guide and the instrument may be defined as P_i . Material of measured thickness L may then be positioned between the light guide and the instrument and the laser power detected by the instrument may then be measured as P_t . For accuracy the measurement may be done repeatedly with one layer of the material, giving a P_t^1 , then with a stack of two layers of the material, giving a measurement P_t^2 , then with a stack of three layers of the material, giving a measurement P_t^3 . Two values of α may then be calculated by the relationships:

$$\alpha_1 = \frac{-1}{L} \times \ln \left(\frac{P_t^2}{P_t^1} \right)$$

$$\alpha_2 = \frac{-1}{L} \times \ln \left(\frac{P_t^3}{P_t^2} \right)$$

The value of α for the material may then be calculated as the mean of all the measured values of α , e.g. of α_1 and α_2 .

The process of compounding of the elastomer of this invention is standard in the art of elastomer manufacture, and numerous competent organisations are known which are capable of manufacturing such an elastomer and the appropriate colourant masterbatches.

5 In a further aspect the present invention provides a closure for a pharmaceutical vial made wholly or partly of an elastomer material as described above.

In a further aspect the present invention provides a plunger for a hypodermic syringe made wholly or partly of an elastomer material as described above.

10 The hardness, elasticity etc. of the base TPE selected for use in the manufacture of such a vial closure or syringe plunger may be typical of TPE's presently used for closures and plungers. The base TPE and all other components of the elastomer when used for a vial closure or syringe plunger must be compatible with medical use.

15 Such a closure or plunger is preferably adapted so that a vial or syringe provided with such a closure or plunger may be used in a process in which the point of a hollow needle is passed through the closure part or plunger so that the point is within the vial, a fluid contents material such as a drug or vaccine solution or suspension, or a reconstitution fluid is introduced into the vial or syringe through
20 the needle, the needle is then withdrawn, and the small residual puncture hole left by the needle in the closure or plunger is sealed by heat sealing of the outside of the closure or plunger, e.g. using a focussed laser beam.

WO-A-02/064439 discloses a vial closure of two-part construction, i.e. having a base portion, and a re-sealable portion made of a fusible material. WO-A-
25 03/0287785 discloses a syringe plunger having a penetrable region which is fusible. The closure and plunger of the latter two aspects of this invention may be constructed in the manner described respectively in WO-A-02/064439 and WO-A-03/0287785, and the elastomer material of this invention may be used as the fusible material thereof.

30 Advantageously, the closure and plunger of the latter two aspects of this invention may be of single-part construction, i.e. made entirely of the elastomer material of this invention.

A closure of this aspect of the invention may be of generally conventional construction, but for example a suitable construction of a closure part for a vial which may be made from the elastomer material of the invention is described as the "closure part" in applicant's GB 0219152.6 (filed 16 August 2002) and GB
5 0304268.6 (filed 26 February 2003) and the PCT application claiming priority therefrom.

Such a closure may comprise an upper part comprising a closure wall and descending therefrom a lower plug part which can fit into the mouth opening of a vial, and preferably at least the upper surface of the closure wall, preferably the
10 entire closure wall, preferably the whole of the closure part is made of the thermoplastic elastomer material of the invention, so that a puncture hole through the closure wall formed as a result of filling the vial using a hollow needle as described above may be sealed by thermal sealing, e.g. using a focused light beam such as a laser. The closure wall normally extends across the mouth opening of the
15 vial. Typically the closure wall of such a closure has a thickness ca. 2 mm. Such a closure may also comprise a flange part to form a seal between the closure and the rim of the mouth opening of the vial. Typically the closure wall of such a closure has a thickness ca. 2 mm.

Therefore the invention further provides a closure for a pharmaceutical vial
20 having a closure wall comprised of an elastomer material such that when laser light is directed on the outer surface of the closure wall 99% of the laser power is absorbed within 0.5 – 2.5 mm depth from the outer surface, preferably within 1.0 – 2.5 mm⁻¹ preferably 1.5 – 2.2 mm⁻¹, ideally as close to 1.5 mm⁻¹ as can be achieved, e.g. 1.4 – 1.6 mm⁻¹, with the effect of melting the material. The elastomer material
25 of the present invention provides the advantage that under irradiation from a focussed 980nm laser of power less than 20W, typically 4 – 10 W, e.g. ca. 8 W the thermoplastic elastomer material easily fuses e.g. after ca. 0.5 - 2 seconds, e.g. 1 second maximum irradiation, and sets on cooling without emission of significant quantities of contaminating smoke. The defined absorption coefficient has the
30 advantage that when the closure wall of such a closure is of a conventional thickness e.g. ca. 2.0mm a negligible amount of laser power, typically less than 6% may penetrate through the closure to reach the interior.

Therefore in a further aspect the present invention provides a closure for a pharmaceutical vial, or a plunger for a hypodermic syringe, made wholly or partly of a thermoplastic elastomer compounded with a colourant to the extent that less than 6%, preferably less than 4%, preferably less than 2%, of laser light of
5 wavelength 980nm and incident power up to 8W penetrates through the closure to reach the interior of the vial or plunger.

Preferred elastomer materials, colourants and compositions for such an elastomer material are as discussed above.

The closure and plunger of this invention may be made by methods
10 involving conventional injection moulding processes.

In a further aspect a process is provided for introducing a substance into a vial comprising: providing a vial having a mouth opening closed by a closure of this invention, passing a hollow needle through the closure, introducing the substance into the vial via the needle, withdrawing the needle from the vial and closure, and
15 sealing the small residual puncture hole in the closure by heat sealing, i.e. by heating the material adjacent the puncture site so that the material fuses, e.g. using a focussed laser beam, then allowing the material to cool and set.

In a further aspect a process is provided for introducing a substance into a hypodermic syringe comprising: providing a syringe having a plunger of this
20 invention, passing a hollow needle through the plunger, introducing the substance into the vial via the needle, withdrawing the needle from the syringe and plunger, and sealing the small residual puncture hole in the plunger by heat sealing, e.g. using a focussed laser beam.

The invention will now be described by way of non-limiting example only.
25 Fig. 1 shows a longitudinal section through a pharmaceutical vial and a closure made of elastomer material of this invention.

Example 1: Elastomer material compositions.

(Example No) Base TPE	Masterbatch Wt%	Carrier	Pigment wt%	Pigment Colour
(1) Evoprene Super G948	1.48	EVA	40	Pantone 5497C
(2) Evoprene TS2525	1.48	EVA	40	Pantone 5497C
(3) Cawiton PR5947 A	8.2	LDPE	18	Pantone 5497C
(4) C-Flex R70-001	8	Polypropylene		Pantone 5497C

In these Examples the base elastomer, in a grade suitable for use in a pharmaceutical vial closure, was supplied from the suppliers indicated below. In each Example the colourant Masterbatch is composed of the carrier compounded with the pigment at the indicated pigment loading. In each Example the pigment is made up of the pigments white 6, black 7, green 7 and blue 29 in suitable proportions to achieve the Pantone 5497 colour. In each Example the Masterbatch was made up by a commercial colourant compounder using known grades of the carrier material suitable for use in a pharmaceutical vial closure and given the Compounder's reference as below.

Ex. No.	Base elastomer supplier	Compounder	Masterbatch Ref.
(1)	Alphagary (GB)	Polycolour Plastics (GB)	31622-M2
(2)	Alphagary (GB)	Polycolour Plastics (GB)	31622-M2
(3)	Wittenburg (NL)	Qolortech B.V (NL)	Masterminds PE Green 60-11.3570
(4)	CPT (USA)	Clariant (USA)	PA5497 Misty green

The compounding procedure for making up the colourant Masterbatch and then compounding the base elastomer with the Masterbatch was entirely conventional in the elastomer art. A requirement was set that 99% of laser power of 8W at 980nm was to be absorbed after passage through a maximum of 2mm of the elastomer i.e. an absorption coefficient α as defined above of 2mm^{-1} , optimally 1.5mm^{-1} . The base elastomer was taken and its absorption coefficient α was measured. Various blends of base elastomer and the colourant masterbatch were then compounded with various proportions % of the masterbatch and the absorption coefficient α for each blend was measured so a graph of α against % masterbatch could be made. From this graph and based on the Beer-Lambert law a compound of base elastomer and masterbatch could be made having the desired absorption coefficient α .

Each of the elastomer materials of Examples 1 – 4 had an absorption coefficient α as defined above of ca. 1.5mm^{-1} for laser light of wavelength 980nm, measured using the method described above, i.e. 99% of such laser light at a power 8W was absorbed in this thickness of the elastomer material. This resulted in melting of the elastomer material adjacent a puncture hole in ca. 1 second.

The elastomer materials of Examples 1-4 could easily be made by injection moulding into vial closures of conventional shape or as disclosed in GB 0219152.6 and GB 0304268.6 using a conventional injection moulding procedure.

Such a vial closure is shown in Fig. 1, in which vial 10 shown in longitudinal sectioned view has an upper mouth opening 11 closed by a closure 20. Closure 20 comprises an upper closure wall 21 from which descends a plug part 22 which fits in a tight sealing fit in the mouth opening 11 of vial 10. The closure also has a peripheral flange 23 which mates with a flange 12 of the vial 10. The closure 20 is held in place on vial 10 as shown by clamp part 30 which snap-fits over the flange 12. The central part 21A of closure wall 21 has a thickness ca. 2mm.

When made of any of the materials of Examples 1-4 above it was found that such closures 20 could easily be punctured by a needle (not shown) passed in a downward direction as shown through the central part 21A of closure wall 21, and

when the needle was subsequently withdrawn the residual puncture hole could be sealed in a few seconds by melting the surrounding elastomer material with a focused laser beam of wavelength 980nm and power 8W, then allowing the melted material to cool and set. Negligible smoke or other volatile potential contaminants
5 were emitted from the elastomer material during this process. Also it was found that with a closure wall (i.e. the part 24 identified in Fig. 1 of GB 0219152.6 and GB 0304268.6) thickness of 1-2mm less than 6% of the laser power was transmitted through the closure wall to reach the interior of the vial.

Claims.

1. An elastomer material having an absorption coefficient for laser light of $0.5 - 2.5 \text{ mm}^{-1}$.
- 5 2. An elastomer material according to claim 1 comprising a base thermoplastic elastomer compounded with a colourant to have the absorption coefficient for laser light of $0.5 - 2.5 \text{ mm}^{-1}$.
- 10 3. An elastomer material according to claim 1 or claim 3 wherein the base TPE has a melting point of 200°C or less.
4. An elastomer material according to claim 2 or 3 wherein the base TPE is a styrene-ethylene/butylene-styrene thermoplastic elastomer.
- 15 5. An elastomer material according to claim 2 or 3 wherein the base TPE is selected from the materials Evoprene™, Cawiton™, and C-Flex.
6. An elastomer material according to claim 2 or 3 wherein the base TPE is a
20 styrene/butadiene/styrene tri-block copolymer or styrene-(butadiene/butylene)-styrene tri-block copolymers.
7. An elastomer material according to any one of claims 2 to 6 wherein the colourant comprises a pigment or mixture thereof mixed with a carrier material.
- 25 8. An elastomer material according to claim 7 wherein the pigment or mixture thereof has the grey-green colour Pantone 5497C or a similar grey colour.
9. An elastomer material according to claim 7 or 8 wherein the colourant
30 comprises a mixture of the pigments: white 6, black 7, green 7 and blue 29.

10. An elastomer material according to claim 7, 8 or 9 wherein the carrier material comprises ethylene vinyl acetate, low density polyethylene or polypropylene
- 5 11. An elastomer material according to any one of claims 7 to 10 wherein the colourant mixture comprises 10 – 50 wt. % pigment, the balance up to 100% comprising the carrier material.
- 10 12. An elastomer material according to any one of claims 7 to 11 comprising 1 – 15wt. % of colourant the balance up to 100% comprising the base TPE.
- 15 13. An elastomer material according to claim 1 which comprises Evoprene™ Super G, compounded with 1 – 5 wt% of a colourant masterbatch comprising an EVA carrier with 35 - 45wt% of pigment of a colour Pantone 5497 or similar colour.
- 20 14. An elastomer material according to claim 1 which comprises Evoprene™ TS2525, compounded with 1 – 5 wt% of a colourant masterbatch comprising an EVA carrier with 35 - 45wt% of pigment of a colour Pantone 5497 or similar colour.
- 25 15. An elastomer material according to claim 1 which comprises Cawiton™ PR5947, compounded with 3 - 15 wt% of a colourant masterbatch comprising an LDPE carrier with 15 – 20 wt% of pigment of a colour Pantone 5497 or similar colour.
- 30 16. An elastomer material according to any one of the preceding claims which in a thickness ca 2mm allows less than 6% of laser power up to 8W incident power to pass through.
17. An elastomer material according to any one of the preceding claims having an absorption coefficient in the range 1.0 – 2.5 mm⁻¹.

18. An elastomer material according to claim 17 having an absorption coefficient $1.5 - 2.2 \text{ mm}^{-1}$.
- 5 19. An elastomer material according to claim 18 having an absorption coefficient $1.4 - 1.6 \text{ mm}^{-1}$.
20. A closure for a pharmaceutical vial made wholly or partly of an elastomer material as claimed in any one of the preceding claims.
- 10 21. A plunger for a hypodermic syringe made wholly or partly of an elastomer material as claimed in any one of claims 1 to 19.
- 15 22. A closure according to claim 20 or a plunger according to claim 21 made entirely of the elastomer material..
- 20 23. A closure for a pharmaceutical vial having a closure wall comprised of an elastomer material such that when laser light is directed on the outer surface of the closure wall 99% of the laser power is absorbed within $0.5 - 2.5 \text{ mm}$ depth from the outer surface with the effect of melting the material.
- 25 24. A closure for a pharmaceutical vial, or a plunger for a hypodermic syringe, made wholly or partly of a thermoplastic elastomer compounded with a colourant to the extent that less than 6% of laser light of wavelength 980nm at an incident laser power up to 8W penetrates through the closure to reach the interior of the vial or plunger.
- 30 25. A process for introducing a substance into a vial comprising: providing a vial having a mouth opening closed by a closure as claimed in any one of claims 20 or 22 to 24, passing a hollow needle through the closure, introducing the substance into the vial via the needle, withdrawing the needle from the vial and closure, and sealing the residual puncture hole in the closure by heat sealing.

26. A process for introducing a substance into a hypodermic syringe comprising:
providing a syringe having a plunger as claimed in claim 21 or 24, passing a hollow
needle through the plunger, introducing the substance into the vial via the needle,
5 withdrawing the needle from the syringe and plunger, and sealing the residual
puncture hole in the plunger by heat sealing.




Fig. 1